Eli Lilly (LLY) said Friday that new results showed that 50% of patients with moderate-to-severe atopic dermatitis, or eczema, achieved completely clear skin at three years after receiving single monthly maintenance injection of Ebglyss.
The patients were among the Ebglyss week 16 responders from the monotherapy trials, the company said.
Eli Lilly also said 87% achieved or maintained "almost-clear" skin at three years with Ebglyss based on data from a long-term extension study.
Ebglyss was approved by the US Food and Drug Administration in 2024 as a first-line monotherapy biologic treatment option after topical prescription therapies.
The company also said that based on additional studies, Ebglyss improved symptoms such as itch, skin pain and sleep loss due to itch.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.